Posted in Insurance, Payer Updates, Training, Updates

BCBS NY Medicaid: Ocrevus/Vyepti Medical Step Therapy Notice

Starting for DOS on 04/01/2021 and thereafter, the following medications will be added to BCBS NY Medicaid Step Therapy.

Step therapy review applies upon precertification initiation or renewal in addition to the current medical necessity review.

To see the full clinical criteria/medical policy for Ocrevus, please click here.

To see the full clinical criteria/medical policy for Eptinezumab, please click here.

Posted in Insurance, Payer Updates, Training, Updates

Anthem BCBS (NY) Site of Care review for long-acting colony-stimulating factors, 06/01/2021

This policy is for site of care medical necessity review and it only applies to administration performed in an outpatient hospital setting.

This does not apply to requests for review of medication administration performed in a non-hospital setting or as part of an inpatient stay. Reviews also do not apply when Empire is the secondary payer.

The medical necessity Review will be performed by AIM Specialty Health® (AIM).

AIM will evaluate the clinical information in the request to the CG-MED-083 policy, or Site of Care: Specialty Pharmaceuticals, to determine if the hospital-based outpatient setting is medically necessary for the medication administration. To see the policy and what clinical considerations are taken into account for determination, visit Empire’s Medical Policy and Clinical UM Guideline page and type Specialty in the search field. You may contact AIM to request a peer-to-peer discussion before or after the determination.

The following codes apply to this policy:

To Submit a request for review:

Starting May 16, 2021, ordering providers may submit prior authorization requests for the hospital outpatient site of care for these medications for dates of service on or after June 1, 2021 to AIM in one of the following ways:

  • Access AIM ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
  • Access AIM via the Availity Web Portal at availity.com
  • Call the AIM Contact Center toll-free number: 1- 877-430-2288, Monday–Friday, 8:00 a.m.–6:00 p.m. ET.

This review does not apply to the following plans: BlueCard®, Federal Employee Program® (FEP®), Medicaid, Medicare Advantage, Medicare Supplemental plans. Providers can view prior authorization requirements for Empire members on the Medical Policy & Clinical UM Guidelines page at empireblue.com/provider.

**Note: In some plans “level of care” or another term such as “setting” or “place of service” may be the term used in benefit plans, provider contracts or other materials instead of or in addition to “site of care” and in some plans, these terms may be used interchangeably.  For simplicity, we will hereafter use “site of care.”**

Posted in Insurance, Training, Updates

Anthem Medi-Cal: Radiotherapies and radioimmunotherapies will require prior authorization 04/01/2021

PA requirements will be added to the following codes:

  • A9543 Injection, Yttrium Y-90 ibritumomab tiuxetan (Zevalin)
  • A9590 Injection, Iodine I-131, iobenguane, 1 mCi (Azedra)
  • A9513 Injection, Lutetium Lu 177, dotatate, therapeutic, 1 millicurie (Lutathera)
  • A9606 Injection, Radium ra-223 dichloride, therapeutic, per microcurie (Xofigo)

Effective 04/01/2021 the above codes will require an auth.

Providers have 2 ways to order a PA:

Federal and state law, as well as state contract language, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.